Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern

Most FDA advisory committee members say potential mortality issue seen in community acquired bacterial pneumonia patients can be addressed postmarket.

More From BioPortfolio on "Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern"